REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.25
-0.39 (-4.00%)
Nov 21, 2024, 12:23 PM EST - Market open

Company Description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease.

In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies.

Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States.

REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

REGENXBIO Inc.
REGENXBIO logo
Country United States
Founded 2008
IPO Date Sep 17, 2015
Industry Biotechnology
Sector Healthcare
Employees 344
CEO Curran Simpson

Contact Details

Address:
9804 Medical Center Drive
Rockville, Maryland 20850
United States
Phone 240 552 8181
Website regenxbio.com

Stock Details

Ticker Symbol RGNX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001590877
CUSIP Number 75901B107
ISIN Number US75901B1070
Employer ID 47-1851754
SIC Code 2836

Key Executives

Name Position
Curran M. Simpson M.S. President, Chief Executive Officer and Director
Dr. Olivier Danos Ph.D. Executive Vice President and Chief Scientific Officer
Vittal K. Vasista Advisor
Dr. Stephen Pakola M.D. Executive Vice President and Chief Medical Officer
Mitchell Chan M.B.A. Executive Vice President and Chief Financial Officer
Patrick J. Christmas II, J.D. Executive Vice President and Chief Legal Officer
Shiva G. Fritsch Chief Communications and People Officer
Dr. Ram Palanki Pharm.D. Executive Vice President of Commercial Strategy and Operations

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 10-Q Quarterly Report
Nov 6, 2024 8-K Current Report
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 17, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 17, 2024 8-K Current Report
Aug 6, 2024 8-K Current Report
Aug 1, 2024 144 Filing
Aug 1, 2024 10-Q Quarterly Report